​

Mainz Biomed B.V. Stock (NASDAQ:MYNZ)

RevenueOwnershipFinancialsChart
Mainz Biomed B.V. by TradingView

Previous Close

$5.18

52W Range

$0.18 - $7.95

50D Avg

$3.83

200D Avg

$1.31

Market Cap

$11.22M

Avg Vol (3M)

$2.25M

Beta

0.08

Div Yield

-

MYNZ Company Profile

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

Show More

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

DE

Employees

65

IPO Date

Nov 05, 2021

Website

MYNZ Performance

MYNZ Financial Summary

Dec 23Dec 22Dec 21
Revenue$895.48K$529.88K$577.35K
Operating Income$-26.64M$-26.17M$-9.38M
Net Income$-26.30M$-26.45M$-12.07M
EBITDA$-24.67M$-25.65M$-9.27M
Basic EPS$-1.62$-1.87$-1.67
Diluted EPS$-1.62$-1.87$-1.67

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
STIMNeuronetics, Inc.
BNRBurning Rock Biotech Limited
PREPrenetics Global Limited
DRIODarioHealth Corp.
APDNApplied DNA Sciences, Inc.
BDSXBiodesix, Inc.
NOTVInotiv, Inc.
SERASera Prognostics, Inc.
FONRFONAR Corporation
NDRAENDRA Life Sciences Inc.
LABStandard BioTools Inc.
MDXHMDxHealth SA